Corwin Thomas, DO
Cardiovascular Disease · Lafayette, LANPI 1013920362
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.5%), other and education — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Angiodynamics, Inc. at 50.3% of the total. Reporting peaked in 2021 at $8,622 and has fallen 84.3% since, to $1,358 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 567 payments — averaging $53.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$15K
- Penumbra, Inc.$3K
- Abiomed$1K
- Boston Scientific$920
- Johnson & Johnson$896
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$759
- plus $9K from 41 others
What the payments were for
- Travel & lodging$2,3238%
- Food & beverage$12,81642%
- Education$6,84923%
- Other$8,20027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$14,200
- Indigo System$2,527
- Auryon$817
- Impella$453
- Diamondback Peripheral$257
- JARDIANCE$234
- Diamondback Coronary$231
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$166
- ELCA$145
- Vascular Lithotripsy$129
- BRILINTA$125
- NEXLIZET$124
- NEXLETOL$124
- RYBELSUS$122
- Kerendia$116
- GENERAL ATHERECTOMY$111
- SYNERGY$111
- VYNDAQEL$109
- Abre$106
- LUX-DX$104
How this compares
$30,188 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvkeezaEvinacumab-Dgnb | 13 | $566,932 |
| XareltoRivaroxaban | 447 | $334,813 |
| EliquisApixaban | 261 | $176,396 |
| EntrestoSacubitril/Valsartan | 163 | $133,557 |
| KerendiaFinerenone | 136 | $105,837 |
| OzempicSemaglutide | 82 | $81,069 |
| JardianceEmpagliflozin | 80 | $64,008 |
| VascepaIcosapent Ethyl | 143 | $54,888 |
| FarxigaDapagliflozin Propanediol | 51 | $39,755 |
| Repatha SureclickEvolocumab | 51 | $33,097 |
| BrilintaTicagrelor | 56 | $32,136 |
| MounjaroTirzepatide | 25 | $26,193 |
| Ranolazine ErRanolazine | 478 | $22,982 |
| VerquvoVericiguat | 31 | $20,620 |
| ZontivityVorapaxar Sulfate | 28 | $16,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Evkeeza | $218 | $566,93213 claims |
| Johnson & JohnsonXarelto | $896 | $334,813447 claims |
| PfizerEliquis | $552 | $176,396261 claims |
| NovartisEntresto | $531 | $133,557163 claims |
| BayerKerendia | $525 | $105,837136 claims |
| Novo NordiskOzempic | $387 | $81,06982 claims |
| AstraZenecaFarxiga, Brilinta | $605 | $71,891107 claims |
| Boehringer IngelheimJardiance | $638 | $64,00880 claims |
| MerckVerquvo, Zontivity | $353 | $37,29959 claims |
| Esperion Therapeutics, Inc.Nexlizet | $463 | $12,69832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Lafayette
- Wade MayLafayette$30K
- Brent RochonLafayette$21K
- Syed Fazal Ur RehmanLafayette$12K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.